Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended approval of liraglutide 3.0 mg  to treat obesity in children aged 12 years or older.

The higher dose, used to combat obesity in adults, is now approved for this younger age group based on a trial published in January this year , which showed significant weight reductions with liraglutide 3.0 mg/day versus placebo, in line with the established effect in adults.

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

A randomized trial demonstrates significant reductions in visceral adipose tissue in people with obesity but without diabetes taking the glucagon-like peptide-1 receptor agonist liraglutide.

A randomized trial supports giving people with obesity liraglutide to maintain weight loss after an 8-week diet, particularly if it is combined with regular vigorous exercise.

Findings from a pilot study suggest that the GLP-1 receptor agonist liraglutide might be beneficial for the management of obesity in people with schizophrenia, schizoaffective disorder, or first-episode psychosis.

Liraglutide 3.0 mg boosts weight loss in obese adolescents receiving lifestyle therapy, show the findings of a phase 3 trial.

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

Adding liraglutide 3.0 mg to intensive behavioral therapy increases weight loss in overweight or obese people with insulin-treated type 2 diabetes, results of the phase 3 SCALE Insulin trial show.

A small neuroimaging study suggests that taking liraglutide over the medium to long term may provoke a counter-regulatory response in the brain, diminishing the medication’s weight loss effect.

Adding liraglutide to continuous subcutaneous insulin infusion significantly reduces glycated hemoglobin without increasing hypoglycemia in overweight and obese people with type 1 diabetes and suboptimal glycemic control, Danish research shows.

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

Factors including bodyweight and treatment duration predict response to liraglutide in patients with type 2 diabetes treated in clinical practice, report researchers.

Obese patients with type 2 diabetes who receive treatment intensification with liraglutide may have better glycemic control than those given basal insulin, researchers report.

Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.

Liraglutide enhances the positive effects of lifestyle intervention on weight loss and glycemic control in patients with prediabetes, show the 3-year outcomes of the SCALE Obesity and Prediabetes trial.